patented technology to grow and expand adult Stem Cells

Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place

Free
Message: 8/10 Pluristem in Key Discussions with Europe s Adaptive Pathways Group

Pluristem in Key Discussions With Europe's Adaptive Pathways Group on Phase II Protocol in Critical Limb Ischemia by Global Newswire

Share
New Message
Please login to post a reply